FDA approves new treatment for a type of late-stage lung cancer

FDA approves new treatment for a type of late-stage lung cancer

The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as

4
Like
Save

Comments

Write a comment

*